/PRNewswire/ Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with.
Morphogenesis, Inc. entered into a stock purchase agreement for the gross proceeds of $15 million on May 23, 2023. The transaction included participation from returning investor CohBar, Inc.. |
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. and Morphogenesis, Inc. is fair to CohBar shareholders.
Halper Sadeh encourages CohBar. | May 23, 2023
CohBar, Inc. (CWBR) and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock merger.